Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Issue 21 (2nd July 2014)

• Record Type: Journal Article
• Authors: Hassan, Raffit; Sharon, Elad; Thomas, Anish; Zhang, Jingli; Ling, Alexander; Miettinen, Markku; Kreitman, Robert J.; Steinberg, Seth M.; Hollevoet, Kevin; Pastan, Ira
• Is Part Of: Cancer. Volume 120:Issue 21(2014)
• Page Start: 3311
• Page End: 3319
• Publication Date: 2014-07-02
• Subjects: mesothelin -- pleural mesothelioma -- SS1P -- immunotoxin; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28875
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: The primary objective of this study was to determine the safety and maximum tolerated dose (MTD) of the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) (a recombinant antimesothelin immunotoxin consisting of a murine antimesothelin variable antibody fragment [Fv] linked to PE38, a truncated portion of Pseudomonas exotoxin A) in combination with pemetrexed and cisplatin in chemotherapy‐naive patients with advanced malignant pleural mesothelioma (MPM). Secondary objectives included tumor response, SS1P pharmacokinetics, and serum biomarkers of response. METHODS: Chemotherapy‐naive patients with stage III or IV, unresectable, epithelial or biphasic MPM and normal organ functions were eligible. Pemetrexed (500 mg/m 2 on day 1) and cisplatin (75 mg/m 2 on day 1) were administered every 3 weeks for up to 6 cycles with escalating doses of SS1P administered intravenously on days 1, 3, and 5 during cycles 1 and 2. Tumor response was evaluated every 6 weeks. RESULTS: Twenty‐four patients received SS1P at 4 dose levels from 25 to 55 mcg/kg. Grade 3 fatigue was dose‐limiting in 1 patient at 55 mcg/kg. The MTD of SS1P was established as 45 mcg/kg. Other grade 3 toxicities associated with SS1P included hypoalbuminemia (21%), back pain (13%), and hypotension (8%). Of 20 evaluable patients, 12 (60%) had a partial response, 3 had stable disease, and 5 had progressive disease. Of 13 patients who received the MTD, 10 (77%) had a partial response, 1 had stable disease, and 2 had progressive disease. Objective radiologic responses were associated with significant decreases in serum mesothelin ( P =.0030), megakaryocyte potentiating factor ( P =.0005), and cancer antigen 125 ( P < .0001). CONCLUSIONS: SS1P given with pemetrexed and cisplatin is safe and well tolerated and exhibits significant antitumor activity in patients with unresectable, advanced pleural mesothelioma. Serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 levels correlated with objective tumor responses. Cancer 2014;120:3311–3319 . Published 2014. This article is a U.S. Government work and is in the public domain in the USA. Abstract : In this first clinical evaluation of the combination of an immunotoxin with chemotherapy, SS1P, an antimesothelin immunotoxin, was combined with pemetrexed and cisplatin in chemotherapy‐naive patients who had advanced malignant pleural mesothelioma. The results from this phase 1 trial demonstrate that SS1P and chemotherapy can be safely combined with no overlapping toxicity. In addition, the objective tumor response rate for the combination is higher than expected with chemotherapy alone and provides a strong rationale for a randomized trial to confirm this finding.